Immune checkpoint inhibitors could restore immune surveillance to attack tumor through targeting CTLA-4, PD-1 or PD-L1, and have achieved huge success. However, immune-related adverse events (irAEs) have been attracting attention as their application is expanding. Gastritis is relatively rare as a subtype of irAEs, particularly severe gastritis. Guidelines on its clinical management still remain undefined due to limited data. Sintilimab is a PD-1 inhibitor approved in China. Here we offer a case of sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction. Conventional proton pump inhibitors and mucosal protective agents did not take effect, so glucocorticoid was chosen. This severe gastritis was successfully cured finally. Our report describing its clinical performances, endoscopic characteristics and treatments, could assist clinicians to better know this rare irAE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2023-0325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: A case of sintilimab-induced recurrent diabetic ketoacidosis and thyroid dysfunction in a patient with advanced cervical carcinoma.
Front Immunol
October 2024
Department of Information, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but can trigger immune-related adverse events (irAEs), particularly affecting the endocrine system with issues like diabetes and thyroid problems.
- A case study of a 50-year-old woman treated with sintilimab for cervical cancer revealed she developed severe ICI-induced diabetes (ICI-DM) and thyroid issues, showing rapid progression unlike typical type 1 diabetes.
- Early detection and treatment of these irAEs, including monitoring blood glucose and thyroid levels, are essential to prevent serious complications and improve patient outcomes when using ICIs.
Case report: A rare case of anti-PD-1 sintilimab-induced agranulocytosis/severe neutropenia in non-small cell lung cancer and literature review.
Front Oncol
June 2024
Intensive Care Medicine, Affiliated Loudi Hospital, Hengyang Medical School, University of South China, Loudi, Hunan, China.
Immune checkpoint inhibitors (ICIs) demonstrate unique advantages in the treatment of lung cancer and are widely used in the era of immunotherapy. However, ICIs can cause adverse reactions. Hematological toxicities induced by immunotherapy are relatively rare.
View Article and Find Full Text PDFSintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review.
Immunotherapy
March 2024
Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China.
Immune checkpoint inhibitors could restore immune surveillance to attack tumor through targeting CTLA-4, PD-1 or PD-L1, and have achieved huge success. However, immune-related adverse events (irAEs) have been attracting attention as their application is expanding. Gastritis is relatively rare as a subtype of irAEs, particularly severe gastritis.
View Article and Find Full Text PDFSintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report.
Front Immunol
November 2023
Department of Neurology, Jiangdu People's Hospital affiliated to Yangzhou University, Yangzhou, China.
The use of immune checkpoint inhibitors (ICIs) has shown remarkable efficacy in the treatment of various malignancies, significantly reshaping cancer treatment. However, as a result of the widespread use of ICIs, several immune-related adverse events (iRAEs) have emerged, some of which can be rare and potentially fatal. In this paper, we reported the earliest case of Sintilimab used in the treatment of esophageal cancer with severe inflammatory myopathy (involving the cardiac, respiratory, and skeletal muscles)in China.
View Article and Find Full Text PDFSintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review.
J Cardiovasc Dev Dis
October 2023
Department of Cardiology, Zhongnan Hospital, Wuhan University, No. 169 Donghu Road, Wuchang District, Wuhan 430071, China.
Immune checkpoint inhibitors (ICIs) have emerged as a powerful and efficacious therapeutic approach for many cancer patients. Sintilimab is a fully human IgG4 monoclonal antibody that binds with programmed cell death receptor-1 (PD-1) to block its interaction with ligands, thereby enhancing the antitumor effects of T cells. However, ICIs may induce immune-related adverse events (irAEs) in various systems and organs, with fulminant myocarditis being the most severe one.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!